Related Experiment Videos
The Perth endoluminal bifurcated graft system--development and early experience
M M Lawrence-Brown1, D Hartley, S T MacSweeney
1Vascular Surgery Department, Royal Perth Hospital, Western Australia.
Summary
A novel bifurcated endoluminal graft system was developed for abdominal aortic aneurysms. This system achieved an 81% satisfactory aneurysm exclusion rate in patients, demonstrating potential for endovascular repair.
Area of Science:
- Vascular Surgery
- Biomedical Engineering
- Medical Device Development
Background:
- Abdominal aortic aneurysms (AAAs) pose significant risks, necessitating effective treatment options.
- Endovascular aneurysm repair (EVAR) offers a less invasive approach but requires specialized graft systems.
- Developing reliable bifurcated grafts is crucial for expanding EVAR applicability to complex anatomies.
Purpose of the Study:
- To develop and evaluate a novel, reliable endoluminal bifurcated graft system for treating infrarenal abdominal aortic aneurysms.
- To assess the feasibility and efficacy of this new graft system in a patient cohort.
Main Methods:
- A life-size model of the aorta and iliac arteries was used for developing a bifurcated graft system.
- The system utilized self-expanding Gianturco and 'Z' stents within a Dacron graft.
- Deployment involved a novel technique using both femoral arteries for a bifurcated and extended straight graft placement.
Main Results:
- The bifurcated graft system was deployed in 21 patients, achieving satisfactory aneurysm exclusion in 17 (81%).
- Median follow-up of 30 weeks showed sustained aneurysm exclusion in successfully treated patients.
- No renal artery complications were observed despite stent placement across renal artery origins in 85% of cases.
Conclusions:
- The developed bifurcated endoluminal graft system is a viable option for treating infrarenal abdominal aortic aneurysms.
- This system demonstrates promising results in terms of aneurysm exclusion and safety.
- The ability to deploy a bifurcated system expands the potential for endovascular treatment of AAAs.